ODYSSEY ALTERNATIVE: Monoclonal antibody alirocumab vs. ezetimibe in patients with statin intolerance

Statin intolerance limits patients’ capacity to reach their LDL goals. This study compared the new drug alirocumab vs. ezetimibe in patients with statin intolerance and muscular symptoms (≥2 statin intolerance at minimum doses). Study design included placebo administration and statin intolerance testing. LDL baseline was 194 mg/dl.

Conclusion

Alirocumab reduced LDL levels significantly compared to ezetimibe after 24 weeks in a statin intolerant population with high baseline LDL levels. In addition, it showed a much lower tolerance rate compared to atorvastatin

Descargar (PDF, Unknown)

Patrick M Moriarty
2014-11-18

Original title: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm.

*

Top